Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
34
NAUT Quote, Financials, Valuation and Earnings
Last price:
$1.93
Seasonality move
:
-17.65%
Day range:
$1.95 - $2.02
52-week range:
$0.62 - $2.54
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.48x
Volume:
172.3K
Avg. volume:
309.1K
1-year change:
11.24%
Market cap:
$250.1M
Revenue:
--
EPS (TTM):
-$0.50
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NAUT
Nautilus Biotechnology, Inc.
|
-- | -$0.15 | -- | -- | $2.50 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
GDRX
GoodRx Holdings, Inc.
|
$194.5M | $0.09 | -2.9% | 420.34% | $4.88 |
|
PRLD
Prelude Therapeutics, Inc.
|
-- | -$0.36 | 412.5% | -65.45% | $4.00 |
|
SRTS
Sensus Healthcare, Inc.
|
$6.3M | -$0.11 | -36.14% | -25.98% | $7.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NAUT
Nautilus Biotechnology, Inc.
|
$1.98 | $2.50 | $250.1M | -- | $0.00 | 0% | -- |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$4.71 | $42.50 | $14.3M | -- | $0.00 | 0% | -- |
|
GDRX
GoodRx Holdings, Inc.
|
$2.75 | $4.88 | $933.4M | 32.01x | $0.00 | 0% | 1.26x |
|
PRLD
Prelude Therapeutics, Inc.
|
$2.45 | $4.00 | $154M | -- | $0.00 | 0% | 16.52x |
|
SRTS
Sensus Healthcare, Inc.
|
$3.79 | $7.33 | $62.3M | 34.65x | $0.00 | 0% | 1.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NAUT
Nautilus Biotechnology, Inc.
|
13.77% | 4.123 | 25.3% | 14.63x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
GDRX
GoodRx Holdings, Inc.
|
47.58% | 0.637 | 37.77% | 2.62x |
|
PRLD
Prelude Therapeutics, Inc.
|
23.37% | -0.451 | 21.91% | 3.02x |
|
SRTS
Sensus Healthcare, Inc.
|
1.03% | 1.791 | 1.03% | 4.98x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NAUT
Nautilus Biotechnology, Inc.
|
-$1.6M | -$15.5M | -27.96% | -32.15% | -- | -$11.5M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
GDRX
GoodRx Holdings, Inc.
|
$161.2M | $26.4M | 2.63% | 4.78% | 13.48% | $58M |
|
PRLD
Prelude Therapeutics, Inc.
|
$6.1M | -$20.4M | -90.83% | -106.36% | -314.12% | -$19.1M |
|
SRTS
Sensus Healthcare, Inc.
|
$2.7M | -$2.6M | -5.58% | -5.65% | -37.32% | $2.3M |
Nautilus Biotechnology, Inc. vs. Competitors
-
Which has Higher Returns NAUT or AIM?
AIM ImmunoTech has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of -10571.43%. Nautilus Biotechnology, Inc.'s return on equity of -32.15% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital NAUTNautilus Biotechnology, Inc.-- -$0.11 $196.1M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About NAUT or AIM?
Nautilus Biotechnology, Inc. has a consensus price target of $2.50, signalling upside risk potential of 26.26%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Nautilus Biotechnology, Inc., analysts believe AIM ImmunoTech is more attractive than Nautilus Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAUTNautilus Biotechnology, Inc.2 0 0 AIMAIM ImmunoTech1 0 0 -
Is NAUT or AIM More Risky?
Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock NAUT or AIM?
Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAUT or AIM?
Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Nautilus Biotechnology, Inc.'s net income of -$13.6M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAUTNautilus Biotechnology, Inc.-- -- -- -$13.6M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns NAUT or CVM?
CEL-SCI Corp. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of --. Nautilus Biotechnology, Inc.'s return on equity of -32.15% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital NAUTNautilus Biotechnology, Inc.-- -$0.11 $196.1M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About NAUT or CVM?
Nautilus Biotechnology, Inc. has a consensus price target of $2.50, signalling upside risk potential of 26.26%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 802.34%. Given that CEL-SCI Corp. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe CEL-SCI Corp. is more attractive than Nautilus Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAUTNautilus Biotechnology, Inc.2 0 0 CVMCEL-SCI Corp.1 0 0 -
Is NAUT or CVM More Risky?
Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock NAUT or CVM?
Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAUT or CVM?
Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Nautilus Biotechnology, Inc.'s net income of -$13.6M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAUTNautilus Biotechnology, Inc.-- -- -- -$13.6M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns NAUT or GDRX?
GoodRx Holdings, Inc. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of 0.57%. Nautilus Biotechnology, Inc.'s return on equity of -32.15% beat GoodRx Holdings, Inc.'s return on equity of 4.78%.
Company Gross Margin Earnings Per Share Invested Capital NAUTNautilus Biotechnology, Inc.-- -$0.11 $196.1M GDRXGoodRx Holdings, Inc.82.22% $0.00 $1.1B -
What do Analysts Say About NAUT or GDRX?
Nautilus Biotechnology, Inc. has a consensus price target of $2.50, signalling upside risk potential of 26.26%. On the other hand GoodRx Holdings, Inc. has an analysts' consensus of $4.88 which suggests that it could grow by 77.58%. Given that GoodRx Holdings, Inc. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe GoodRx Holdings, Inc. is more attractive than Nautilus Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAUTNautilus Biotechnology, Inc.2 0 0 GDRXGoodRx Holdings, Inc.6 5 0 -
Is NAUT or GDRX More Risky?
Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GoodRx Holdings, Inc. has a beta of 1.470, suggesting its more volatile than the S&P 500 by 47.004%.
-
Which is a Better Dividend Stock NAUT or GDRX?
Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GoodRx Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. GoodRx Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAUT or GDRX?
Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than GoodRx Holdings, Inc. quarterly revenues of $196M. Nautilus Biotechnology, Inc.'s net income of -$13.6M is lower than GoodRx Holdings, Inc.'s net income of $1.1M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while GoodRx Holdings, Inc.'s PE ratio is 32.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus 1.26x for GoodRx Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAUTNautilus Biotechnology, Inc.-- -- -- -$13.6M GDRXGoodRx Holdings, Inc.1.26x 32.01x $196M $1.1M
-
Which has Higher Returns NAUT or PRLD?
Prelude Therapeutics, Inc. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of -303.46%. Nautilus Biotechnology, Inc.'s return on equity of -32.15% beat Prelude Therapeutics, Inc.'s return on equity of -106.36%.
Company Gross Margin Earnings Per Share Invested Capital NAUTNautilus Biotechnology, Inc.-- -$0.11 $196.1M PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M -
What do Analysts Say About NAUT or PRLD?
Nautilus Biotechnology, Inc. has a consensus price target of $2.50, signalling upside risk potential of 26.26%. On the other hand Prelude Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 63.27%. Given that Prelude Therapeutics, Inc. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe Prelude Therapeutics, Inc. is more attractive than Nautilus Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAUTNautilus Biotechnology, Inc.2 0 0 PRLDPrelude Therapeutics, Inc.2 0 0 -
Is NAUT or PRLD More Risky?
Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prelude Therapeutics, Inc. has a beta of 1.065, suggesting its more volatile than the S&P 500 by 6.517%.
-
Which is a Better Dividend Stock NAUT or PRLD?
Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prelude Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. Prelude Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAUT or PRLD?
Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than Prelude Therapeutics, Inc. quarterly revenues of $6.5M. Nautilus Biotechnology, Inc.'s net income of -$13.6M is higher than Prelude Therapeutics, Inc.'s net income of -$19.7M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while Prelude Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus 16.52x for Prelude Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAUTNautilus Biotechnology, Inc.-- -- -- -$13.6M PRLDPrelude Therapeutics, Inc.16.52x -- $6.5M -$19.7M
-
Which has Higher Returns NAUT or SRTS?
Sensus Healthcare, Inc. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of -13.7%. Nautilus Biotechnology, Inc.'s return on equity of -32.15% beat Sensus Healthcare, Inc.'s return on equity of -5.65%.
Company Gross Margin Earnings Per Share Invested Capital NAUTNautilus Biotechnology, Inc.-- -$0.11 $196.1M SRTSSensus Healthcare, Inc.39.41% -$0.06 $51.7M -
What do Analysts Say About NAUT or SRTS?
Nautilus Biotechnology, Inc. has a consensus price target of $2.50, signalling upside risk potential of 26.26%. On the other hand Sensus Healthcare, Inc. has an analysts' consensus of $7.33 which suggests that it could grow by 93.49%. Given that Sensus Healthcare, Inc. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe Sensus Healthcare, Inc. is more attractive than Nautilus Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAUTNautilus Biotechnology, Inc.2 0 0 SRTSSensus Healthcare, Inc.2 0 0 -
Is NAUT or SRTS More Risky?
Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sensus Healthcare, Inc. has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.559%.
-
Which is a Better Dividend Stock NAUT or SRTS?
Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sensus Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. Sensus Healthcare, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAUT or SRTS?
Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than Sensus Healthcare, Inc. quarterly revenues of $6.9M. Nautilus Biotechnology, Inc.'s net income of -$13.6M is lower than Sensus Healthcare, Inc.'s net income of -$943K. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while Sensus Healthcare, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus 1.74x for Sensus Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAUTNautilus Biotechnology, Inc.-- -- -- -$13.6M SRTSSensus Healthcare, Inc.1.74x 34.65x $6.9M -$943K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
